Effects of Photobiomodulation in Salivary Analysis of Chronic Renal Failure Patients
Xerostomia, Chronic Renal Failure
About this trial
This is an interventional treatment trial for Xerostomia
Eligibility Criteria
Inclusion Criteria:
- Stable cardiopulmonary and neurological conditions;
- Hb> 10.9 g / dl and Hematocrit> 33;
- Absence of acute systemic infectious processes;
- Blood pressure <140 mmHg and PAd <90 mmHg in at least two measurements in two subsequent dialysis;
- No hypervolemia;
- Patients over 18 years-old;
- Signed a statement of informed consent.
Exclusion Criteria:
- Patients in intensive care unit;
- Hemodynamic instability, signs and symptoms of uremic syndrome related to the cardiovascular and neurological systems;
- Presence of acute systemic infectious processes;
- Presence of acute cardiovascular disease, systolic blood pressure > 141 mmHg and / or diastolic blood pressure > 91 mmHg;
- Significant anemia (Hb <11 g / dl and Hto <33%);
- Photosensitivity;
- Pregnancy.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Photobiomodulation group
Placebo group
Patients were submitted to three sessions of PBM (baseline, 7 and 14 days). PBMT was administered by a single professional using a continuous wave AsGaAl diode laser (Photon Lase III - DMC, São Paulo, Brazil) with a wavelength of 808 nm (infrared). Irradiation was performed in punctual contact mode (ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point). A total of 20 points were applied in each session/day being three extraoral points in the parotid region (right and left n=6), three points in buccal mucosa (right and left, n=6), two extraoral (right and left, n=4) and two intraoral (right and left, n=4) points in the submandibular and sublingual regions.
Patients were submitted to same protocol as the photobiomodulation group, but the laser was turned off.